01 November 2011

India power lending No easy solutions ::Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


India power lending
No easy solutions
Event
􀂃 We went to a discussion on credit quality for power sector lenders organised
by rating agency CRISIL yesterday. The panel members were from CRISIL,
power lenders and corporates. The consensus was on the need for urgent
sector reforms to avert systemic shocks with the hope that the very urgent
nature of problems shocks politicians into action.
Impact
􀂃 How bad can it really get for the power lenders? The answer: really bad if
no steps are taken, bad if reforms are undertaken now. CRISIL estimates a
tariff increase of 47% is needed for state distribution companies to break
even, given the current losses. This we believe is a large number and it is
unlikely that state governments will have the political will to implement.
􀂃 Putting some numbers to it. CRISIL believes that assuming reforms, 4.5%
of total lender’s exposure of Rs5tn could be at risk. We believe the estimate is
too low, given that ~30% of this debt itself is to large loss making discoms of
financially weak states. (See page 3 for our estimates of possible
restructurings in the power sector).
􀂃 What do the companies say? Things likely to get much worse before
getting better. Corporate delegates believe that things will get much worse
before getting better. New capacity is unlikely to be set up on a large scale
until sector issues like fuel supply, tariff revision and SEB losses get sorted
out. This may take a couple of years as state governments may continue to
postpone problems until there is no escape. Lenders themselves have
become very cautious while lending to projects, even as promoters are
focussing on finishing existing projects in time rather than building new
capacities. As a result the 100,000MW planned generation capacity addition
in the 12th Five Year Plan is likely to remain a pipedream.
􀂃 Fuel supply is a critical issue- Capacity for taking imported coal to plants is
a bottleneck. A bigger concern is the stagnating production of Coal India, the
monopoly domestic coal supplier. Increased proportion of imported coal is
likely to significantly increase the cost of production of power, impacting the
viability of projects.
􀂃 Bottlenecks at policy level as well. The central government is trying to push
state governments to implement reforms but that depends on ‘politics’. State
governments would like to postpone the timing and quantum of tariff hikes as
much as possible. Quality of data available for calculating tariff revisions
needed, is also suspect but info systems are being improved.
􀂃 What happened in early 2000’s (in the past round of restructurings)? The
principle amount was repaid in entirety. However interest rate was lowered
from ~20% to 8.5% and the penal interest payment also waived.
Outlook
􀂃 Many of the problems of the sector we believe are built into the current
valuations of power financiers. However sustainable rerating may only happen
once tangible reforms take place on ground.

HDFC Bank Will you ever disappoint? :Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


HDFC Bank
Will you ever disappoint?
Event
 2QFY12 - 30% for the umpteenth time, as expected provisions used to
smoothen: HDFC Bank’s net profit numbers hardly surprise in any way as
they continue reporting ~30% YoY growth. As expected they smoothed the
numbers through the provisions line item which was down 19% YoY and 17%
QoQ. In 1QFY12, they made floating provisions of Rs2.5bn, which was less
this quarter. Maintain Outperform with TP of Rs615.
Impact
 Loan growth slows down but due to higher base: HDFC Bank funded the
telecom sector for 3G financing in 1HFY11, which was absent this quarter.
Hence loan growth on a reported basis was 20% YoY; however adjusted for
the short-term one-off loans of last year, loan growth was healthy at 25%.
 Moving up the risk curve, credit costs unsustainable at these levels:
Looking at HDFC Bank’s retail portfolio, which registered 34% YoY growth,
segments like personal loans, credit cards, business banking, etc, have been
growing at a very rapid pace. However if we look at credit costs, they are just
at 80-90bps for 1HFY12, which is clearly unsustainable in our view.
 Sharp decline in CASA a worry – just watch out for other banks: HDFC
Bank, as the best bank in the country with respect to liabilities franchise, saw
a sharp 170 bps QoQ decline in CASA to 47.3%. Management attributed this
to higher traction in term deposits relative to savings deposits due to elevated
interest rate levels and migration from savings to term. Consequently margins
also declined by 10bps QoQ to 4.1% inline with our expectations. We believe
even other banks are likely to see a sharp decline in CASA going ahead.
 Stable asset quality remains the biggest positive: Asset quality remained
stable with the slippage ratio at less than 100bps. The NPL coverage ratio
including floating provisions is highest in the sector at 125%+. Restructured
standard advances at 10bps are also among the lowest in the sector.
 Key conference call takeaways: 1) Retail loan demand remains good
despite high interest rates because of increases in wages and, hence,
affordability is good. The bank is gaining market share across several retail
loan categories. 2) Despite an increase in retail assets and 15bps increase in
investment yields, a lower CASA and higher mobilisation of term deposits
affected NIMs. NIMs are expected to be in a range of 3.9-4.2%. 3) Floating
provisions are created not to smooth out earnings but to create a counter
cyclical cushion and they are included as a part of Tier-II capital.
Earnings and target price revision
 No change.
Price catalyst
 12-month price target: Rs615.00 based on a Gordon growth methodology.
 Catalyst: Continued strong earnings growth and asset quality improvements
Action and recommendation
 HDFC Bank is one of our top financials picks in India: Reiterate Outperform

FII DERIVATIVES STATISTICS FOR 01-Nov-2011

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



BUY
SELL
OPEN INTEREST AT THE END OF THE DAY

No. of contracts
Amt in Crores
No. of contracts
Amt in Crores
No. of contracts
Amt in Crores
INDEX FUTURES
71270
1873.53
90508
2371.50
576390
15105.27
INDEX OPTIONS
507413
13244.16
451726
11839.18
1440378
37877.85
STOCK FUTURES
56937
1505.97
73138
1874.18
1149745
28498.14
STOCK OPTIONS
13384
346.48
12960
329.88
20992
539.55


BSE, Bulk deals, 1/11/2011

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Deal DateScrip CodeCompanyClient NameDeal Type *QuantityPrice **
1/11/2011532683AIA EngineeringNALANDA INDIA EQUITY FUND LIMITEDB1200000310.00
1/11/2011532683AIA EngineeringRELIANCE CAPITAL TRUSTEE CO A/C RELIANCE GROWTH FUNDS1200000310.00
1/11/2011531560Aroma EnterprisesVOLGA INTERNATIONAL LIMITEDB3600089.95
1/11/2011531560Aroma EnterprisesSHREEBHUVANAKARAM TRADINVEST PRIVATE LTDB3600089.95
1/11/2011531560Aroma EnterprisesSHREE SUPRINIT TRADINVEST PVT.LTDB3600089.95
1/11/2011531560Aroma EnterprisesSHREEMALLIKARJUN TRADINVEST PRIVATELIMITEDB3600089.95
1/11/2011531560Aroma EnterprisesPINAC STOCK BROKERS PRIVATE LIMITEDB3600089.95
1/11/2011531560Aroma EnterprisesPRIYAL INTERNATIONAL PRIVATE LIMITEDB20000090.00
1/11/2011531560Aroma EnterprisesKANCHANBHAI BALDEVBHAI PATELB2700089.50
1/11/2011531560Aroma EnterprisesSHEETAL P JAINS8000089.95
1/11/2011531560Aroma EnterprisesCHUNILAL MISHRIMAL SANGHVIS2700089.50
1/11/2011531560Aroma EnterprisesMANOJ PRAKASH SANGHVIS30000089.98
1/11/2011531568Ashutosh PaperKPM INFOTECH PRIVATE LIMITEDB46800174.41

NSE, Bulk deals, 01-Nov-2011

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


DateSymbolSecurity NameClient NameBuy / SellQuantity TradedTrade Price /
Wght. Avg.
Price
Remarks
01-Nov-2011AANJANEYAAanjaneya Lifecare LtdDOMEBELL ELECTRONICS INDIA PVT.LTDBUY1,00,000417.00-
01-Nov-2011AANJANEYAAanjaneya Lifecare LtdJHELUM HOLDING PRIVATE LIMITEDSELL1,00,000417.00-
01-Nov-2011AMRUTANJANAmrutajan Health LtdRAHUL DOSHIBUY28,031805.43-
01-Nov-2011AMRUTANJANAmrutajan Health LtdRAHUL DOSHISELL28,031803.28-
01-Nov-2011INDIABULLSIndiabulls Financial ServOBERON LIMITEDSELL20,17,816150.27-
01-Nov-2011LMLLML Ltd.TRANSGLOBAL SECURITIES LTD.BUY5,01,27911.02-

1/11/11:: Categories Turnover (Rs. crore) Clients NRI Proprietary Trade Data

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��




Categories Turnover
(Rs. crore)
ClientsNRIProprietary
Trade DateBuySalesNetBuySalesNetBuySalesNet
1/11/111,568.131,480.0688.060.550.83-0.28454.42454.57-0.15
31/10/111,460.211,449.6010.620.440.430.01519.29516.512.78
28/10/111,561.801,758.67-196.870.750.700.05578.56516.6361.93
Nov , 111,568.131,480.0688.060.550.83-0.28454.42454.57-0.15
Since 1/1/11414,786.38419,428.95-4,642.57297.19206.5090.70120,755.05119,919.11835.94

1/11/11: FII & DII Turnover (BSE + NSE)

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


FII & DII Turnover (BSE + NSE)
(Rs. crore)
FIIDII
Trade DateBuySalesNetBuySalesNet
1/11/111,914.741,935.40-20.66666.561,239.97-573.41
31/10/112,587.452,228.67358.78945.291,221.65-276.36
28/10/115,496.623,330.412,166.211,200.252,278.66-1,078.41
Nov , 111,914.741,935.40-20.66666.561,239.97-573.41
Since 1/1/11   *521,313.59539,311.49-17,997.90242,933.40221,461.3021,472.10

Zee Entertainment Bracing for a cold winter : Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Zee Entertainment
Bracing for a cold winter
Event
 Post 2Q results we now expect FY12 to be a tepid year for ad revenues (now
expecting 2% vs. 6% earlier). We expect this to be mitigated at the EPS level
by aggressive cost cuts and a cap on Sports losses. We remain cautious with
a TP of Rs110.
Impact
 Conference call takeaways:
Ad environment remains volatile and it’s difficult to provide a trend vs.
earlier indication of high single digit growth in FY12.
Increasing the number of fresh hours of programming to 32-33 per week
from 29 earlier on Zee TV. This would keep margins lower vs. FY11.
Tax rates for the year to remain at ~31% as Sports segment losses in 1H
have depressed the reported tax rate.
 Ad revenue estimate cut further. We have been cautious on the ad growth
outlook for Zee and now expect the FY12 growth rate to remain muted at 2%.
We recognise that our revised assumptions still build in ~5% YoY growth for
the company in each of the last two quarters.
 GEC programming costs to pick up but sports losses being capped. The
only positive surprise in the quarter was on programming costs at 45% of
revenues vs. our est. of 48.5%. Zee realises that its GEC channel rankings
have taken a beating and plans to invest in programming to win share back
from peers. Even so, we have reduced our overall programming cost estimate
since sports losses are likely to be capped at Rs1bn.
 Accounting policy change due to Media Pro. Zee has started reporting
domestic subscription revenues net of expenses. This also has helped the
company to post a 630bps jump in its margins. We learnt from the
management that earlier financials for the subsidiary Zee Turner were
consolidated line-by-line but given the distribution JV formation with Star this
is no longer valid.
Earnings and target price revision
 Updating the model for 2Q results. No TP change.
Price catalyst
 12-month price target: Rs110.00 based on a DCF methodology.
 Catalyst: Revival in viewership ratings for key channels
Action and recommendation
 Stay on the sidelines. We expect the stock to remain range bound as the
buyback provides downside support but slowing ad growth would cap any
material stock price appreciation. We prefer Dish TV in the space.

Industrials: Comparing L&T BTG JVs with peers :: Kotak Sec,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Industrials
India
Comparing L&T BTG JVs with peers. We compare L&T-MHI BTG JVs with peers and
highlight key takeaways (1) L&T MHI JVs operate at very low overhead costs ( employee,
and SG&A being 6-7% of sales versus 18-20%), providing a strong competitive base,
(2) currently, the contribution margin is negligible (1.6% in FY2011 versus 37-39%) but
it can scale up as indigenization and learning curve benefits come through and (3) total
gross block at Rs8.2 bn (Rs2.8 bn for boiler) is much smaller than capex envisaged by
others, though a part of it may be with the parent.

Patni - In the price discovery phase; we see value.:: Kotak Sec,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Patni Computer Systems (PATNI)
Technology
In the price discovery phase; we see value. We believe the Patni stock is in the price
discovery phase post majority stake acquisition by iGate. Views on new normal on
revenue growth as well as margins under the new management remain in the
formation phase. iGate’s stance on potential stake reduction to 75% or de-listing also
remains unknown. Nonetheless, strong cash support (37% of market cap) exists and we
see value despite building in conservative estimates. Retain ADD. TP raised to
Rs400/share from Rs300 earlier. Our TP implies a PE of 11.7X CY2012E earnings.

Yes Bank – Margins up, credit quality steady :: RBS

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Yes Bank's 2QFY12 net profit of Rs2.4bn was ahead of our and Street estimates, with qoq NIM
improvement and stable credit quality trends. Higher-than-expected branch add was a positive
surprise in the quarter, even as costs remained under control. We maintain Buy

Global Equity Strategy - Prefer equities to corporate credit ::Credit Suisse,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


● Equities are up 8% since the middle of August, yet credit spreads
have widened slightly. We believe that equities will outperform
high-yield credit in Europe in particular (with the important caveat
that investment grade spreads in the US seem to be overdiscounting
a recession).
● Valuation: Equity's earnings yield still looks attractive relative to
both investment-grade and high-yield corporate bond yields in the
US and Europe (even based on trend earnings). ISM and credit
spreads are consistent with an equity risk premium (ERP) of
6.2%, compared with the current 7.2%.
● Stocks: We flag vulnerable stocks as those whose equity has
outperformed despite their CDS spreads widening by more than
average. Then there are stocks that have underperformed despite
their CDS rising by less than average. We also highlight stocks
that are likely to underperform if the European high-yield spreads
rise, as we think they will, and those that tend to outperform when
the European high-yield spreads rise.

Prefer equities to corporate credit
Equities are up 8% since the middle of August, yet credit spreads
have widened slightly. We believe that equities will outperform high
yield credit in Europe in particular (with the important caveat that
investment grade spreads in the US seem to be over-discounting a
recession).
Valuations: Equities still look cheap relative to credit
Equity’s earnings yield still looks attractive relative to both investmentgrade
and high-yield corporate bond yields in the US and Europe
(even based on trend earnings). ISM and credit spreads are
consistent with an equity risk premium (ERP) of 6.2%, compared with
the current 7.2%.
Economic indicators suggest spreads should be wider
Correlation with lead indicators suggests high-yield spreads should
have widened by more. Default rates implied by high-yield spreads, at
6% on a 12-month trailing basis, look moderate in comparison to the
historic recession default levels of 10%+ (this suggests to us that
European high-yield spreads are likely to move higher, as we think a
Euro-area recession is likely).
Catch-up: The recent relative widening in spreads has only brought
US high-yield spreads back in line with equities (after the decoupling
during 2009/10). There is a similar, though less extreme, story in
Europe.
Turning point: At the market trough, equities have led credit on 5 out
of 7 occasions.

Investment grade is a play on government bonds
Investment grade credit is effectively a play on government bond
yields—yet, yields are hovering at 240-year lows while we believe that
eventually the central banks will print money in the developed world
and equities are an inflation hedge until inflation rises above 4%. Releveraging:
we think with net debt to EBITDA at a 20-year low (in US)
and FCF close to record highs, corporates will re-leverage modestly
via buybacks for investment grade.
Stocks
We flag vulnerable stocks as those whose equity has outperformed
despite their CDS spreads widening by more than average (Banco
Sabadell, Standard Chartered, IP). Stocks that have underperformed
despite their CDS rising by less than average include Vivendi, Allianz,
Smiths, Siemens. Stocks that are likely to underperform if European
high-yield spreads rise, as we think they will, include Air France and
Fraport. Stocks that tend to outperform when European high-yield
spreads rise include Imperial, Novartis and KPN.

Dr Reddy's Labs: Strong quarters ahead : CLSA

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Strong quarters ahead
Dr Reddy’s numbers picked up this quarter led by US launches and
improvement in PSAI growth, a trend that is likely to continue over
coming four quarters resulting strong profit growth. While this quarter’s
margins were slightly lower than expectations due to higher SG&A spend,
high margin US launches (Zyprex, Geodon) and a favourable currency will
aid margins going forward. We expect 40-70% PAT growth over coming
four quarters. Maintain BUY.
Sales growth led by US formulations and PSAI
Dr Reddy’s 2QFY12 sales at Rs22.7bn up 21% YoY are higher than expected
due to strong US and PSAI sales. US sales at Rs6.3bn were up 42% YoY led
by key launches like Allegra D24 and Arixtra during the quarter and due to
market share gains in existing portfolio. We expect US to be very strong over
coming 3-4 quarters led by market share gains and new launches (Zyprexa,
Geodon, Lipitor and Propecia). PSAI segment picked up this quarter after a
couple of weak quarters and will continue to deliver strong numbers over
coming quarters due to a low base and benefit from favourable currency.
Healthy trend in branded markets except India
Domestic formulations grew 10% YoY better than previous quarters
nonetheless lower than market growth rate. Some of leading brands (Nise,
Omez) of Dr Reddy’s are not growing well resulting in a weak India growth.
The company continues to maintain that they will be able to revive growth to
market average levels by 4QFY12. Growth in Russia and CIS markets was
quite strong (22% YoY) primarily led by volume uplift while pricing is marginal
contributor. Do note that Russian currency was unfavourable on a YoY basis
(Ruble weakened against INR) – hence growth is even higher in Ruble terms.
Strong quarters ahead, favourable currency helps further
Over the coming four quarters, we expect very strong numbers both at
revenue and profit levels led by major US launches like Zyprexa (launched on
25th Oct) and Geodon (expected in March 2012). Further a favourable
currency will aid in margin expansion in both US as well as PSAI business. Dr
Reddy’s has added forward covers (now at US$700m+) during Aug-Sept 2011
and have locked their revenues at Rs47-49/ US$. This ensures that they
derive margin benefits even if rupee starts to strengthen next year.

Persistent Systems: In-line 2Q, below the line drives EPS beat :Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Persistent Systems
In-line 2Q, below the line drives EPS
beat
Event
 Persistent reported in-line 2Q results at the top-line and EBIT levels. Strong
cost management and INR depreciation helped the company to improve EBIT
margins by 90bps. The 14% EPS beat was largely driven by below the line
items like higher treasury income, forex gains and a lower tax rate. OP
maintained.
Impact
 Conference call takeaways. 1) Volatility in the market place was the central
theme of the call; 2) no billing rate declines seen by clients; 3) sales and
marketing teams are to focus on new future business from growth areas; 4)
management described demand pipeline as stronger than ever before, though
deal closures are taking longer; and 5) the growth areas continue to contribute
~40% of revenues.
 Cost rationalizations bring margin improvements. Persistent raised its
EBIT margins by 90bps to 13.2% from 12.3%, despite a 9% wage hike to
offshore employees in July. This was made possible by containing sales and
marketing expenses and currency benefits.
 IP initiatives robust with strong top client growth. Persistent spent 5.5%
of the total technical time on IP initiatives (vs. 4.7% in 1Q). This is at a 10-
quarter high. Management explained this citing the bench strength and guided
to ~5% investment levels for the year.
 Tax free dividend income helps reduce the tax rate. We learned from
management that the tax rate for the rest of the year would likely remain at
30%. The lower tax rate of 28% seen in 2Q was due to tax free dividend
income earned by the company in the quarter.
 2Q results – financial and operational details. Persistent reported US$
revenues of US$51m (up 3% QoQ, 27% YoY). INR revenues were Rs2,382m
(up 6% QoQ and 27% YoY) and PAT came in at Rs324m (up 18% QoQ and
down 10% YoY). The company had net employee additions of 280. Utilisation
increased 110bps to 73.8%, and attrition eased off to 17.7% from 18.4%
earlier.
Earnings and target price revision
 Updating our model for 2Q results. Our estimate variance is 1-2% in FY12-13
EPS. No change in TP.
Price catalyst
 12-month price target: Rs350.00 based on a PER methodology.
 Catalyst: Large deal wins.
Action and recommendation
 OP maintained.

Pfizer's branded generics: Would the end be as strong as the beginning?:: Credit Suisse

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


● Pfizer India has significantly stepped up launch of branded
generics (products sourced from other Indian peers) now with total
launches expected to almost double this year compared to 20
launches in the last year. Even next year, Pfizer hopes to maintain
a similar launch rate. In 2Q12, Pfizer launched 11 branded
generics vs four launches in 1Q12.
● These launches are part of Pfizer’s strategy to fill portfolio gaps in
the existing therapies (such as anti-infectives and CNS) and also
to enter new therapies such as anti-diabetes (already entered oral
form through branded generics and insulin through Biocon).
● Pfizer has been more aggressive than GSK Pharma on both
number of launches (GSK aiming at 3-5 branded generics launches
per year) and on pricing. As discussed in CS sector report on 18-
Oct-11 ‘Stay the course,’ we do not view impact of MNCs expansion
as a near-term risk for larger Indian firms and the impact should be
offset/diluted by market share gains from smaller companies. Our
discussions with doctors suggest that they at least take 1-2 years to
switch medicines in chronic therapies.
● Sun should report a strong 2Q12 quarter as Hospira in its results
mentioned yesterday that price erosion on Taxotere has been only
55% vs CS assumption of 70% (vs 45% in the Jun-11 quarter). Our
published net profit expectation for the quarter is Rs4,714 mn.


Oil & Gas Atlas -Is this a market recovery or bear rally? :Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Oil & Gas Atlas
Is this a market recovery or bear rally?
Energy Market Indices WoW Changes
⇒ S&P/TSX Energy Index: +6.3%
⇒ S&P 500 E&P Index: +10.1%
⇒ Oil Service Sector Index: +10.7%
⇒ UK FTSE Oil & Gas Producers Index: +5.2%
⇒ Asia Pacific Oil & Gas Producers Index: +1.9%
Weekly Market Recap
􀂃 Markets rebounded last week as the EU appeared to be progressing on the
current debt crises. On Thursday, Slovakia, the last country that needed to
approve the European Financial Stability Facility, ratified the package. Crude oil
inventories saw a 1.3mmbbl injection versus an expected 0.8mmbbl, however
WTI prices ended the week up 5.3% moving in concert with the broader market
and other major commodities. NYMEX 12-month prices were flat for the week
closing at US$4.07/mmbtu.
􀂃 In Canada, Daylight announced it had entered into an agreement with Chinese
energy company, Sinopec, for the sale of Daylight’s outstanding common shares
for ~C$2.2bn in cash, C$3.2bn in total, including convertible debentures.
Additionally, the National Energy Board of Canada approved the application for
the Kitimat LNG terminal for the KN LNG operating general partnership. The
licence allows the terminal to export 200m tonnes of LNG over a 20-year period.
􀂃 In the Euro E&P space, Tullow was in the middle of corruption allegations and
calls for ministerial resignations in Uganda. Among the non-covered E&Ps,
Rockhopper announced an equity raise and farm-in into neighbouring Desire
Petroleum’s acreage. Ophir announced a recommended all share offer for
Dominion Petroleum. BowLeven had a successful Sapele-3 appraisal well, which
“significantly” extended the oil fairway and lifted the stock up by >60% on Friday.
In the Euro Integrateds space, it emerged that BP will be allowed to participate in
the upcoming US offshore licensing round. BP was also granted approval by the
UK government to proceed with its proposed £4.5bn Claire Ridge development in
the UKNS. The Galp 3Q11 trading update offered few surprises and Repsol
reiterated prior guidance for margin uplift at their Cartagena refinery CMD. Eni
(preliminary) restarted the Greenstream gas pipeline between Libya and Italy.

UBS: UltraTech Cement Q 2FY12 results: Below estimates

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


UBS Investment Research
UltraTech Cement
Q 2FY12 results: Below estimates
􀂄 Event: Results below UBS and consensus estimates
Ultratech reported net sales of Rs39.8bn (+23% y/y, -10% q/q), operating profit of
Rs6.5bn (+49% y/y, -47% q/q; consensus Rs6.9bn) and PAT of Rs2.8bn (+141%
y/y, -59% q/q; below UBS-e of Rs3.2bn and consensus estimate of Rs3.7bn).
Q2FY12 EBITDA/t was about Rs710 per ton (street expectations of about Rs750).
Domestic cement and clinker volumes increased 2% YoY (-5% QoQ) to 8.94mt.
􀂄 Impact: Realizations declined by about 6%, costs per ton up by about 10%
Net cement realisation decreased by about 5.6% QoQ, while total cost per ton
increased by about 10.5% QoQ. Staff costs increased by about 12% QoQ and other
expenditure increased by about 10% (14% YoY, likely led by maintenance works).
Power and fuel costs decreased by about 3% QoQ. Raw material costs per ton
increased by about 3.5% (about 40% including stock adjustments). Interest (-8%
QoQ, -21% YoY) and depreciation (flat QoQ, +2% YoY) were lower than our
expectations.
􀂄 Action: Conference call on Oct 24th, Monday at 10am IST
We have a cautious view on the Indian Cement sector as we expect industry
overcapacity to persist for the next two to there years (and stocks are trading at
premiums to replacement costs). We expect to receive further details on the
management’s outlook and the performance of its overseas subsidiary, Star
Cement, in Grasim’s conference call on Monday, 24th October 2011 at 10am IST.
􀂄 Valuation: Sell rating and PT of Rs950
We value Ultratech at a one-year forward EV/EBITDA of 6x.

UBS: HDFC Bank - Low provisions offset slowing fee

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


UBS Investment Research
HDFC Bank
L ow provisions offset slowing fee
􀂄 In-line results
Net profit of Rs12bn (+31% y/y) was driven by lower provisions while Net interest
income grew at +17% y/y. Key highlights: 1) loans growth of 20% y/y, 7% q/q
(26% after adjusting Telecom lending in Q1FY11), 2) Despite sequential
improvement CASA ratio slipped 180bps q/q to 47.1% - CASA growth at 10%
YoY has been slowest in last 5 years, 3) Provisioning stayed low at 80bps of O/s
loans, 4) Fee income growth of 26% was supported by strong exchange income.
􀂄 Maintain estimates; Lowering provisions and fee income estimates
The bank continued to make excess-provisions in Q2FY12, which we believe
would cushion future earnings when NPL picks up. Considering strong retail asset
quality, we are lowering our LLP forecast to 80bps of loans (from 100 bps) and
also lower non-interest income growth forecast to 24% (from 28%) in FY12. We
maintain loans forecast at 23% CAGR for FY12-13 with stable margins.
Resultantly, we tweak earning estimates by +1% for FY12/14.
􀂄 Valuation premium to stay: Maintain Buy
HDFCB is best positioned among Indian banks given the asset quality headwinds
in the sector, in our view. We believe the stock would sustain its premium
valuations compared to peers given its strong deposit franchise and lower asset
quality risks.
􀂄 Valuations: Raise PT to Rs575 from Rs560
We value the stock using residual income model. At our price target, the stock
trades at 21x FY13E earnings and 3.9x FY13E book.

MindTree Solid quarter – raising EPS and TP :Macquarie Research,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


MindTree
Solid quarter – raising EPS and TP
Event
 MindTree’s 2Q results came in significantly ahead of our estimates. The
positive surprise in revenue growth and margins was supplemented by higher
forex gains in the quarter. We are raising our EPS and target price on the
stock to factor in the beat. MindTree remains our top mid-cap pick in the IT
space.
Impact
 Key highlight of 2Q: Growth momentum. This is the second consecutive
quarter when MindTree has delivered double-digit US$ revenue growth in its
IT Services segment (10% in 2Q vs. 11% in 1Q). This demonstrates
MindTree’s strong execution capability in the mid-cap space.
 Margin improvement driven by top-line growth. Solid revenue growth
helped the company report higher operating margins of 9.1% (+230bps QoQ)
vs. our estimate of a 40bps improvement.
 Forex gains explained. The forex gains of Rs171m can be explained in 4
parts: 1) Restatement of debtors at the ~Rs49 level (vs ~Rs45 in 1Q), 2)
hedges expiring at a rate of Rs47 during Jul-Aug in 2Q, 3) a gain from the
timing of a conversion of USD to INR during 2Q, and 4) an MTM provision on
hedges. The first three resulted in a US$7.2m forex gain partially offset by a
US$3.4m loss due to Point 4. We expect MTCL to report a minor hedging loss
in 3Q. The current hedge position is US$72m @ Rs46 for the rest of FY12.
 2Q results details - revenues cross US$100m mark. MindTree reported US$
revenues of US$101m (up 10% QoQ, 23% YoY), 5% above our estimate. In
INR, MTCL delivered revenues of Rs4,567m (up 11% QoQ and 19% YoY) and
PAT of Rs511m (up 48% QoQ and 120% YoY). Reported PAT includes a onetime
reversal write-back of a contingent liability of Rs37m. Adjusted 2Q EPS at
Rs12.6 would still be materially higher than Street estimate.
 The company announced an interim dividend of Rs2.50, which includes
a special dividend of Rs1 per share.
Earnings and target price revision
 We increase our earnings forecasts by 8% and 5% for FY12/13, respectively,
and raise our target price to Rs470 from Rs440. Details in Figure 4.
Price catalyst
 12-month price target: Rs470.00 based on a PER methodology.
 Catalyst: FY12 Client IT budget finalization.
Action and recommendation
 Reiterate Outperform. We believe the market does not appreciate the
margin expansion that the company can deliver following top-line momentum.
At 8x FY13E, the stock is extremely attractive, in our view.

Lupin: Competition heating up in OCs :: Kotak Sec,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Lupin (LPC)
Pharmaceuticals
Competition heating up in OCs. We view the OC segment with cautious optimism
due to (1) high market shares enjoyed by incumbents, (2) portfolio concentration with
small market size for many of the older non-combination OCs and (3) entry of Sandoz
in 4 big OCs and impending entry of Mylan with 22 products. We think Lupin’s OC
target of US$125 mn by FY2014E is far-fetched. We factor US$50/75 mn in
FY2013/14E. Street estimates, with FY2013E EPS higher than Rs27, are likely to be
factoring aggressive OC sales, an optimistic scenario in our view. Retain ADD; PT Rs530.

Jain Irrigation v/s Netafim India: An Enquiry into Relative Capital Efficiency. Cut PT to Rs125.::JPMorgan,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


 Jain Irrigation v/s Netafim. We compare capital return ratios for JI’s microirrigation
business with Netafim Irrigation India (one of the large privately held
micro-irrigation player in India). In the growth v/s capital deployment tradeoff,
Netafim appears to have fared much better overall. While JI has larger
scale and better margins, it employs significantly higher capital to generate
similar levels of profitability. Our key conclusions are enumerated below:
1. ROCE: JI’s micro-irrigation business generated 16.8% ROCE,
significantly lower than 30.7% ROCE for Netafim India in FY10.
Decomposing the ROCE, we find JI's generating better margins, but
significantly lower capital turnover compared to Netafim.
2. Margins: JI’s micro-irrigation business generated EBIT margins of
19.7% v/s 13.5% for Netafim in FY10.
3. Fixed Asset Turns: Fixed asset turns for JI’s micro-irrigation business
has ranged between 2.7x-3.2x over past 5 years, Netafim has sweated
its fixed assets better at 4.3x-5.4x range over a similar period.
4. Operating Cycle: Operating cycle for JI’s micro-irrigation business
has been 145-205 days over past 5-yrs compared to 60-65 days for
Netafim India. Jain Irrigation’s receivable days of 148 days are
significantly higher than 69 receivable days of Netafim (FY10).
 Stock re-rating difficult in absence of more disciplined approach to capital
deployment: In our view, for the JI stock to re-rate from here, it will have to
demonstrate improved discipline in capital deployment. We believe that besides
improving its receivables cycle (necessary, but not sufficient), JI also needs to
demonstrate better fixed asset sweat, lower capex intensity and divestments of
unrelated ventures like plastic sheets.
 Cut PT to Rs125, maintain UW. We cut EPS estimates for FY12E/FY13E by
14%/12%, factoring lower micro-irrigation sales in FY12E on account of a good
monsoon, and higher interest. Our EPS estimates are 16%-18% below
consensus; we note consensus estimates for FY12/13 have trended down by
15%/13% over past 2 quarters. We thus cut our PT (Sep-12) to Rs125 from
Rs165 now based on SOTP (valuing each business segment on EV/EBITDA).
Key risks to our thesis include higher micro-irrigation growth, increase in govt.
subsidy, improvement in receivables and turnaround of overseas subsidiaries.